Form 4: Jasper Therapeutics COO Buys Shares
Insider Transaction (Form 4)
Matthew E Ros, Chief Operating Officer of Jasper Therapeutics, Inc., purchased 881 shares of common stock on July 20, 2026.
Summary
- Open-market purchase: acquired 881 Non-Voting Convertible Preferred Stock on July 20, 2026; holds 881 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $0, committing personal capital to the stock.
Insider Transactions
Matthew E Ros — Officer (Chief Operating Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-20 | Open-market purchase | Non-Voting Convertible Preferred Stock | 881 | — | — | 881 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-20 | Open-market purchase (881 shares) |
Keywords
insider transaction, Form 4, JSPR, Jasper Therapeutics, Inc., bullish, Matthew E Ros
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.